Our news
- 18/07/2019: Pharegis implemented optimized procedures for state registration of pharmaceuticals in Eurasian Economic Union.
- 20/06/2019: Pharegis updated timelines and practical approaches for Russian and EEU GMP inspection applications and procedures.
- 03/04/2019: Renewed general monographs of Russian state pharmacopeia XIV ed. have been analyzed.
Global industry news
Contact us
- Phone/fax: +7 495 442 37 85
- Phone: +7 985 908 58 18
- E-mail: info@regdrug.com
- pharegis.com | regdrug.com
Activities
Regulatory Events Russia
Russian Regulatory News
Pharegis LLC / ООО "Фареджис"
-
- Business address:
3-1 Begovaya str. ("NordStar Tower", 31st flr), Moscow, Russia 125284
Legal & postal address:
11A-11 Cherkizovskaya B. str., Moscow, Russia 107392
PSRN: 1157746918933
TAX ID (TIN): 7718278100
D-U-N-S: 362071645
-
- +7 495 442 37 85 9am-6pm GMT+3
-
- + 7 495 442 37 85
-
- + 7 985 908 58 18
- http://www.pharegis.com
Regulatory news
Drugs.com - New Drug Approvals
- FDA Approves Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) for the Treatment of Asthma
- FDA Approves Qdolo (tramadol hydrochloride) Oral Solution for the Management of Severe Pain
- FDA Approves Detectnet (copper Cu 64 dotatate injection) Positron Emission Tomography (PET) Agent
- FDA Approves Gavreto (pralsetinib) for the Treatment of Adults With Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer
- FDA Approves Additional Doses of Trulicity (dulaglutide) for the Treatment of Type 2 Diabetes
News and press releases
- Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 14-17 September 2020, CHMP, 18/09/2020
- New oral treatment for moderate to severe atopic dermatitis, CHMP, 18/09/2020
- First treatment for rare metabolic disorder alkaptonuria, CHMP, 18/09/2020
- New treatment for children with chronic kidney disease, CHMP, 18/09/2020
Drugs.com - Clinical Trials
- Daiichi Sankyo Initiates Phase 2 Study of Patritumab Deruxtecan in Patients with HER3 Expressing Advanced Colorectal Cancer Tokyo, Basking Ridge, N.J....
- Clinical Data From Full Phase 1 Cohort Of Investigational Sotorasib Published In New England Journal Of Medicine THOUSAND OAKS,...
- Gilead’s Magrolimab, an Investigational Anti-CD47 Monoclonal Antibody, Receives FDA Breakthrough Therapy Designation for Treatment of Myelodysplastic Syndrome FOSTER CITY,...
- Lilly Announces Proof of Concept Data for Neutralizing Antibody LY-CoV555 in the COVID-19 Outpatient Setting INDIANAPOLIS, Sept. 16,...
PharmaTimes: PharmaTimes Website RSS
- Keytruda/Lenvima combo shows promise in hard-to-treat cancers
- University of Edinburgh spinout Cellinta will develop gene therapies for cancer
- Lynparza scores long-term benefit data in BRCA-mutated ovarian cancer
- CHMP backs seven new meds in September meeting
- BMS' Opdivo wins new NICE lung cancer backing